William S. Marth Chairman
William S. Marth became Chairman of Sorrento and became President and CEO of AMRI Global in January 2014. Mr. Marth most recently served as President and Chief Executive Officer of Teva – Americas, retiring from Teva in 2012. He had previously served as President and Chief Executive Officer of Teva North America from January 2008 to June 2010 and as President and Chief Executive Officer of Teva USA from January 2005 to January 2008. He was previously Executive Vice President and Vice President of Sales and Marketing for Teva USA. Bill currently serves as a senior advisor to Teva Pharmaceuticals. In addition, Bill works with several large equity firms providing guidance on their healthcare investments.
Mr. Marth is recognized as an industry leader with an unparalleled record of commercial success. He was a key strategist in establishing Teva as a leading Specialty Pharmaceutical Company and being ultimately recognized as the worldwide #1 producer of generic drugs. Responsibilities included heading the respiratory, neuroscience, oncology and women’s healthcare divisions plus Select Brands. He is a member of Teva’s global executive management team and Teva Americas’ board of directors since 2007. His experience is Global in all core functional areas including Strategic Planning, IR, R&D, Supply Chain Management and Regulatory. He also served as the architect of the $6.8 billion Cephalon and $7.4 billion Barr Laboratories transactions and integrations. Prior to joining Teva USA, he held various positions with the Apothecon division of Bristol-Myers Squib.
He is a licensed pharmacist and serves on various boards and committees, including AMRI, The University of the Sciences in Philadelphia and the Board of Ambassadors for John Hopkins’ Project RESTORE. Mr. Marth has served as the Chairman of the Board of the Generic Pharmaceutical Association (GPhA) and the American Society for Health-System Pharmacists (ASHP).
Mr. Marth earned his B.Sc. in Pharmacy from the University of Illinois and his M.B.A. from the Keller Graduate School of Management, DeVry University.
David H. Deming
Mr. Deming is a banker with TAG Healthcare Advisors, LLC, a boutique financial advisory firm serving the pharmaceutical, biotech and medical device industries. He has over 35 years of banking experience, of which 27 years were with J. P. Morgan, where he ran the healthcare investment banking group for twelve years.
Mr. Deming has broad experience in capital raising, mergers and acquisitions, and strategic advice. Mr. Deming is on the Boards of IRX Therapeutics, Inc. and St Johnland Nursing Home, Inc.
Kim D. Janda, Ph.D.
Dr. Janda has served as a director since April 2012. Dr. Janda has been the Ely R. Callaway, Jr. Chaired Professor in the Departments of Chemistry, Immunology and Microbial Science at The Scripps Research Institute (“TSRI”) since 1996 and as the Director of the Worm Institute of Research and Medicine (“WIRM”) at TSRI since 2005. Furthermore, Dr. Janda has served as a Skaggs Scholar within the Skaggs Institute of Chemical Biology, also at TSRI, since 1996.
Dr. Janda has published more than 425 original publications in peer-reviewed journals and founded the biotechnological companies CombiChem, Drug Abuse Sciences and AIPartia. Dr. Janda is an associate editor of “Bioorganic & Medicinal Chemistry”, “PLoS ONE” and serves, or has served, on editorial boards of numerous journals including J. Comb. Chem., Chem. Reviews, J. Med. Chem., The Botulinum Journal, Bioorg. & Med. Chem. Lett., and Bioorg. & Med. Chem.
Over a career of more than 25 years, Dr. Janda has provided numerous seminal contributions and is considered one of the first scientists to merge chemical and biological approaches into a cohesive research program. Dr. Janda has served on the Scientific Advisory Boards of Materia and Singapore Ministry of Education.
Dr. Janda holds a B.S. degree from the University of South Florida in Clinical Chemistry and his Ph.D. from the University of Arizona with Robert B. Bates in Natural Product Total Synthesis.
Henry Ji, Ph.D.
Henry Ji, Ph.D. co-founded and has served as a director of Sorrento since January 2006, and as its Chief Executive Officer and President since September 2012. Dr. Ji served as Sorrento’s Chief Scientific Officer from November 2008 to September 2012, and as its Interim Chief Executive Officer from April 2011 to September 2012.
From 2001 to 2002, Dr. Ji served as a VP of CombiMatrix, and was responsible for strategic technology alliances. From 1999 to 2001, Dr. Ji served as Director of Business Development, and in 2001 as VP of Stratagene (later acquired by Agilent Technologies), a biotechnology company. In 1997, Dr. Ji co-founded Stratagene Genomics, a wholly-owned subsidiary of Stratagene Corporation, and served as its President and Chief Executive Officer from its founding until 1999.
Dr. Ji obtained his Ph.D. in Animal Physiology from the University of Minnesota and a B.S. in Biochemistry from Fudan University.
Mr. Shah currently serves as the Chief Executive Officer and board member at Semnur Pharmaceuticals. Prior to Semnur, Mr. Shah was a consultant to several businesses, including Sorrento Therapeutics. From 2011 through 2012, Mr. Shah was the Chief Business Officer of Elevation Pharmaceuticals. Prior to Elevation, Mr. Shah was President of Zelos Therapeutics, where Mr. Shah focused on financing and business development.
Prior to Zelos, Mr. Shah was the SVP and Chief Business Officer at CytRx. Previously, Mr. Shah was Chief Business Officer at Facet Biotech and PDL BioPharma where he completed numerous licensing/ partnering and strategic transactions. Prior to PDL, Mr. Shah was at Bristol-Myers Squibb, most recently as Vice President of Global Marketing where he received the “Presidents Award” for completing one of the most significant collaborations in the company’s history. Previously, Mr. Shah was at F. Hoffmann-La Roche in international marketing and was global business leader for corporate alliances with Genentech and Idec.
Mr. Shah holds an MA in Economics from the University of Akron and an MBA from University of Oklahoma.
Yue Alexander Wu, Ph.D.
Dr. Wu is co-founder, President, Chief Executive Officer and Chief Scientific Officer of Crown Bioscience International, a leading global drug discovery and development solutions company, which he co-founded in 2006. From 2004 to 2006, Dr. Wu was Chief Business Officer of Starvax International Inc. in Beijing, China, a biotechnology company focusing on oncology and infectious diseases.